Curis Lifesciences Limited to Invest in Uninova Lifesciences, Appoints Auditors
Curis Lifesciences Limited announced a strategic investment in Uninova Lifesciences Private Limited on March 28, 2026. The company will acquire 51% of the issued and paid-up share capital of Uninova Lifesciences Private Limited for a Purchase Consideration of INR 20,65,500. This acquisition will make Uninova Lifesciences Private Limited a subsidiary of Curis Lifesciences Limited.Uninova Lifesciences Private Limited was incorporated on October 22, 2021, and has a paid-up share capital of INR 30,00,000. It recorded an audited turnover of INR 5.39 crores for the Financial year 2024-25, INR 5.11 crores for FY 2023-24 and INR 2.90 crores for FY 2022-23. The company is engaged in the manufacturing and trading of pharmaceutical products and operates primarily in India.
The acquisition aligns with Curis Lifesciences Limited’s strategic growth initiatives aimed at business expansion and diversification within the pharmaceutical industry. The transaction is expected to be completed within 30 days, subject to the fulfillment of conditions outlined in the Share Purchase Agreement.
Separately, the Board of Directors appointed M/s NGST & Associates as the Internal Auditors of the Company for the Financial Year 2025-26 and M/s. Sachin Thakkar and Associates, Company Secretaries, Peer Reviewed Audit firm as the Secretarial Auditors of the Company for the Financial Year 2025-26.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.